eTheRNA

Executive Summary

eTheRNA is a clinical-stage biotechnology company specializing in mRNA-based vaccines and therapeutics, leveraging its proprietary nucleoside-modified mRNA platform and novel lipid nanoparticle (LNP) delivery systems. Founded in 2013 and headquartered in Cambridge, MA, the company focuses on infectious disease and oncology indications, aiming to induce robust and durable immune responses. With $39 million raised to date, eTheRNA has advanced its lead programs into Phase 2 clinical trials, demonstrating the potential of its technology to address high unmet medical needs in both prophylactic and therapeutic settings. The company's ongoing Phase 2 trials are generating key data on safety and immunogenicity, with results expected to inform further development and potential regulatory interactions. eTheRNA's innovative LNP formulations offer competitive advantages in delivery efficiency and tolerability, positioning the company as a potential partner for larger pharmaceutical firms. Upcoming catalysts include clinical data readouts, progress toward Phase 3 initiation, and strategic partnering opportunities that could provide non-dilutive funding and accelerate development. With a strong scientific foundation and a focused pipeline, eTheRNA is poised to contribute to the rapidly evolving mRNA therapeutics landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead infectious disease vaccine70% success
• Q1 2027Initiation of Phase 3 trial for oncology program60% success
• H2 2026Strategic partnership or licensing deal for LNP platform55% success